Biomaterial strategies to reduce implant-associated infections

International Journal of Artificial Organs

Volumn 30, Issue 9, 2007, Pages 828-841

  Qiu, Y ^a   Zhang, N ^a,b   An, Y H ^b   Wen, Xuejun ^a,b  

^a AMRL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Biomaterials; Implant associated infections; Surface modification

Indexed keywords

BACTERIA; BIOMATERIALS; CELL SIGNALING; CYTOLOGY;

'CURRENT; ANTI-ADHESIVE SURFACES; ANTIBACTERIALS; BIOFILM FORMATION; CELL-CELL COMMUNICATIONS; IMMUNE DEPRESSION; IMPLANT INFECTIONS; IMPLANT-ASSOCIATED INFECTION; OPERATING ROOM ENVIRONMENT; SURFACE-MODIFICATION;

SURFACE TREATMENT;

ALBUMIN; ANTIINFECTIVE AGENT; BIOMATERIAL; BIOSURFACTANT; BMAP 28; BONE CEMENT; CARBOXYMETHYLCELLULOSE; CHITOSAN; CIPROFLOXACIN; COPPER ION; FLUCLOXACILLIN; FOSFOMYCIN; HYDROXYAPATITE; IMMUNOGLOBULIN G; LYSOSTAPHIN; MACROGOL; METAL ION; MICROSPHERE; PEPTIDE; POLYMER; POLYSACCHARIDE; POLYURETHAN; PYRIDINE; SILASTIC; SILVER DERIVATIVE; SILVER NITRATE; SULFADIAZINE SILVER; SURFACTANT; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTISEPSIS; BACTERIUM ADHERENCE; BINDING COMPETITION; BIODEGRADABILITY; BIOENGINEERING; BONE MARROW TOXICITY; BONE REMODELING; BURN; CONTROLLED RELEASE FORMULATION; DEVICE INFECTION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; HEALTH HAZARD; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOTHERAPY; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; MATERIAL COATING; NANOTECHNOLOGY; NONHUMAN; OPSONIZATION; OSTEOMYELITIS; PROSTHESIS INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; URINE CATHETER;

EID: 36049018891     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000913     Document Type: Review

References (146)

1. Vinh DC, Embil JM. Device-related infections: a review. J Long Term Eff Med Implants 2005; 15: 467-88.
2. Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev 2006; 35: 780-9.
3. Sanderson PJ. Infection in orthopaedic implants. J Hosp Infect 1991; 18 (suppl A): S367-75.
4. Strachan CJ. The prevention of orthopaedic implant and vascular graft infections. J Hosp Infect 1995; 30 (suppl): 54-63.
5. Campoccia D, Montanaro L, Arciola CR. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials 2006; 27: 2331-9.
6. Cordero J, Munuera L, Folgueira MD. Influence of bacterial strains on bone infection. J Orthop Res 1996; 14: 663-7.
7. Schierholz JM, Beuth J, Rump A, Konig DP, Pulverer G. Novel strategies to prevent catheter-associated infections in oncology patients. J Chemother 2001; 13 (Spec No 1): 239-50.
8. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
9. An YH, Friedman RJ. Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res 1998; 43: 338-48.
10. Reid G. Applications from bacterial adhesion and biofilm studies in relation to urogenital tissues and biomaterials: a review. J Ind Microbiol 1994; 13: 90-6.
11. Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother 1992; 36: 1347-51.
12. Andersson J, Bexborn F, Klinth J, Nilsson B, Ekdahl KN. Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. J Biomed Mater Res A 2006; 76: 25-34.
13. Chen H, Brook MA, Chen Y, Sheardown H. Surface properties of PEO-silicone composites: reducing protein adsorption. J Biomater Sci Polym Ed 2005; 16: 531-48.
14. Kim JH, Kim SC. Effect of synthesis temperature of PEO-grafted PU/PS IPNs on surface morphology and in vitro blood compatibility. J Biomater Sci Polym Ed 2003; 14: 601-14.
15. Groll J, Fiedler J, Engelhard E, Ameringer T, Tugulu S, Klok HA, Brenner RE, Moeller M. A novel star PEG-derived surface coating for specific cell adhesion. J Biomed Mater Res A 2005; 74: 607-17.
16. Nagelschmidt M, Saad S. Influence of polyethylene glycol 4000 and dextran 70 on adhesion formation in rats. J Surg Res 1997; 67: 113-8.
17. Nnebe IM, Tilton RD, Schneider JW. Direct force measurement of the stability of poly(ethylene glycol)-polyethylenimine graft films. J Colloid Interface Sci 2004; 276: 306-16.
18. Wei J, Bagge-Ranv D, Gram L, Kingshott R Stainless steel modified with poly(ethylene glycol) can prevent protein adsorption but not bacterial adhesion. Colloids Surf B Biointerfaces 2003; 32: 275-91.
19. Kingshott P, Wei J, Bagge-Ravn D, Gadegaard N, Gram L. Covalent attachment of poly(ethylene glycol) to surfaces, critical for reducing bacterial adhesion. Langmuir 2003; 19: 6912-21.
20. Park JH, Cho YW, Kwon IC, Jeong SY, Bae YH. Assessment of PEO/PTMO multiblock copolymer/segmented polyurethane blends as coating materials for urinary catheters: in vitro bacterial adhesion and encrustation behavior. Biomaterials 2002; 23: 3991-4000.
21. Boulmedais F, Frisch B, Etienne O, Lavalle P, Picart C, Ogier J, Voegel JC, Schaaf P, Egles C. Polyelectrolyte multilayer films with pegylated polypeptides as a new type of anti-microbial protection for biomaterials. Biomaterials 2004; 25: 2003-11.
22. Harris LG, Tosatti S, Wieland M, Textor M, Richards RG. Staphylococcus aureus adhesion to titanium oxide surfaces coated with non-functionalized and peptide-functionalized poly(L-lysine)-grafted-poly(ethylene glycol) copolymers. Biomaterials 2004; 25: 4135-48.
23. Dong BY, Manolache S, Somers EB, Wong ACL, Denes FS. Generation of antifouling layers on stainless steel surfaces by plasma-enhanced crosslinking of polyethylene glycol. J Appl Polym Sci 2005; 97: 485-97.
24. Yoo HJ, Kim HD. Properties of crosslinked blends of pellethene and multiblock polyurethane containing poly(ethylene oxide) for biomaterials. J Appl Polym Sci 2004; 91: 2348-57.
25. Park KD, Kim YS, Han DK, Kim YH, Lee EH, Suh H, Choi KS. Bacterial adhesion on PEG modified polyurethane surfaces. Biomaterials 1998; 19: 851-9.
26. Roosjen A, van der Mei HC, Busscher HJ, Norde W. Microbial adhesion to poly(ethylene oxide) brushes: Influence of polymer chain length and temperature. Langmuir 2004; 20: 10949-55.
27. Kaper HJ, Busscher HJ, Norde W. Characterization of poly(ethylene oxide) brushes on glass surfaces and adhesion of Staphylococcus epidermidis. J Biomater Sci Polym Ed 2003; 14: 313-24.
28. Sofia SJ, Premnath V, Merrill EW. Poly(ethylene oxide) grafted to silicon surfaces: Grafting density and protein adsorption. Macromolecules 1998; 31: 5059-70.
29. Vacheethasanee K, Marchant RE. Surfactant polymers designed to suppress bacterial (Staphylococcus epidermidis) adhesion on biomaterials. J Biomed Mater Res 2000; 50: 302-12.
30. Lee HJ, Park KD, Park HD, Lee WK, Han DK, Kim SH, Kim YH. Platelet and bacterial repellence on sulfonated poly(ethylene glycol)-acrylate copolymer surfaces. Colloids Surf B Biointerfaces 2000; 18: 355-70.
31. Katanchalee MN. Comblike poly(ethylene oxide)/hydrophobic C-6 branched chitosan surfactant polymers as anti-infection surface modifying agents. Colloids Surf B Biointerfaces 2006; 49:117-25.
32. Bertrand JC, Bonin P, Goutx M, Gauthier M, Mille G. The potential application of biosurfactants in combatting hydrocarbon pollution in marine environments. Res Microbiol 1994; 145: 53-6.
33. Kitamoto D, Isoda H, Nakahara T. Functions and potential applications of glycolipid biosurfactants-from energy-saving materials to gene delivery carriers. J Biosci Bioeng 2002; 94: 187-201.
34. Rodrigues L, Banat IM, Teixeira J, Oliveira R. Biosurfactants: potential applications in medicine. J Antimicrob Chemother 2006; 57: 609-18.
35. Rodrigues L, van der Mei H, Teixeira JA, Oliveira R. Biosurfactant from Lactococcus lactis 53 inhibits microbial adhesion on silicone rubber. Appl Microbiol Biotechnol 2004; 66: 306-11.
36. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis to solid substrata by an adsorbed biosurfactant layer from Lactobacillus acidophilus. Urology 1997; 49: 790-4.
37. Rodrigues L, van der Mei H, Banat IM, Teixeira J, Oliveira R. Inhibition of microbial adhesion to silicone rubber treated with biosurfactant from Streptococcus thermophilus A. FEMS Immunol Med Microbiol 2006; 46: 107-12.
38. Rodrigues LR, Banat IM, van der Mei HC, Teixeira JA, Oliveira R. Interference in adhesion of bacteria and yeasts isolated from explanted voice prostheses to silicone rubber by rhamnolipid biosurfactants. J Appl Microbiol 2006; 100: 470-80.
39. Gan BS, Kim J, Reid G, Cadieux P, Howard JC. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J Infect Dis 2002; 185: 1369-72.
40. Velraeds MM, van de Belt-Gritter B, Busscher HJ, Reid G, van der Mei HC. Inhibition of uropathogenic biofilm growth on silicone rubber in human urine by lactobacilli-a teleologic approach. World J Urol 2000; 18: 422-6.
41. An YH, Blair BK, Martine KL, Friedman RJ. Macromolecule Surface coating for preventing bacterial adhesion. In: Handbook of bacterial adhesion: Principles, Methods, and Applications. YH An, RJ Friedman, eds. Torowa, NJ. Humana Press; 2000. p 609-625.
42. Fletcher M, Marshall KC. Bubble Contact Angle Method for Evaluating Substratum Interfacial Characteristics and Its Relevance to Bacterial Attachment. Appl Environ Microbiol 1982; 44: 184-92.
43. Reynolds EC, Wong A. Effect of adsorbed protein on hydroxyapatite zeta potential and Streptococcus mutans adherence. Infect Immun 1983; 39: 1285-90.
44. Brokke P, Dankert J, Carballo J, Feijen J. Adherence of coagulase-negative staphylococci onto polyethylene catheters in vitro and in vivo: a study on the influence of various plasma proteins. J Biomater Appl 1991; 5: 204-26.
45. Pascual A, Fleer A, Westerdaal NA, Verhoef J. Modulation of adherence of coagulase-negative staphylococci to Teflon catheters in vitro. Eur J Clin Microbiol 1986; 5:518-22.
46. An YH, Stuart GW, McDowell SJ, McDaniel SE, Kang Q, Friedman RJ. Prevention of bacterial adherence to implant surfaces with a crosslinked albumin coating in vitro. J Orthop Res 1996; 14: 846-9.
47. McDowell SG, An YH, Draughn RA, Friedman RJ. Application of a fluorescent redox dye for enumeration of metabolically active bacteria on albumin-coated titanium surfaces. Lett Appl Microbiol 1995; 21: 1-4.
48. Kottke-Marchant K, Anderson JM, Umemura Y, Marchant RE. Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prostheses. Biomaterials 1989; 10: 147-55.
49. Kamath KR, Park K. Surface modification of polymeric biomaterials by albumin grafting using h-irradiation. J Appl Biomater 1994; 5: 163-73.
50. Tseng YC, Mullins WM, Park K. Albumin grafting on to polypropylene by thermal activation. Biomaterials 1993; 14: 392-400.
51. Pavesio A, Renier D, Cassinelli C, Morra M. Anti-adhesive surfaces through hyaluronan coatings. Med Device Technol 1997; 8: 20-1, 24-7.
52. Morra M, Cassineli C. Non-fouling properties of polysaccharide-coated surfaces. J Biomater Sci Polym Ed 1999; 10: 1107-24.
53. Barton AJ, Sagers RD, Pitt WG. Bacterial adhesion to orthopedic implant polymers. J Biomed Mater Res 1996; 30: 403-10.
54. Tang HY, Cao T, Wang AF, Liang XM, Salley SO, McAllister JP, Ng KYS. Effect of surface modification of silicone on Staphylococcus epidermidis adhesion and colonization J Biomed Mater Res A 2007; 80A: 885-94.
55. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983; 11: 161-73.
56. Hoffman J, Larm O, Scholander E. A new method for covalent coupling of heparin and other glycosaminoglycans to substances containing primary amino groups. Carbohydr Res 1983; 117: 328-31.
57. Abu el-Asrar AM, Shibl AM, Tabbara KF, al-Kharashi SA. Heparin and heparin-surface-modification reduce Staphylococcus epidermidis adhesion to intraocular lenses. Int Ophthalmol 1997; 21: 71-4.
58. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns 2007; 33: 139-48.
59. Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000; 26: 131-8.
60. Fox CL. Silver sulphadiazine, addendum to local therapy. In: Modern treatment, Hoeber Medical Division. New York: Harper and Raw, 1967; 1259.
61. Fuller FW, Parrish M, Nance FC. A review of the dosimetry of 1% silver sulfadiazine cream in burn wound treatment. J Burn Care Rehabil 1994; 15: 213-23.
62. Hoffmann S. Silver sulfadiazine: an antibacterial agent for topical use in burns. A review of the literature. Scand J Plast Reconstr Surg 1984; 18: 119-26.
63. Bassetti S, Hu J, D'Agostino RB, Jr., Sherertz RJ. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sutfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemother 2001; 45: 1535-8.
64. George N, Faoagali J, Muller M. Silvazine (silver sulfadiazine and chlorhexidine) activity against 200 clinical isolates. Burns 1997; 23: 493-5.
65. Ostendorf T, Meinhold A, Harter C, Salwender H, Egerer G, Geiss HK, Ho AD, Goldschmidt H. Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients-a double-blind, randomised, prospective, controlled trial. Support Care Cancer 2005; 13: 993-1000.
66. Schmitt SK, Knapp C, Hall GS, Longworth DL, McMahon JT, Washington JA. Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria. J Clin Microbiol 1996; 34: 508-11.
67. Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003; 23: 368-74.
68. Kalfon P, de Vaumas C, Samba D, Boulet E, Lefrant JY, Eyraud D, Lherm T, Santoli F, Naija W, Riou B. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit Care Med 2007; 35: 1032-9.
69. Rupp ME, Fitzgerald T, Marion N, Helget V, Puumala S, Anderson JR, Fey PD. Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. Am J Infect Control 2004; 32: 445-50.
70. Tobin EJ, Bambauer R. Silver coating of dialysis catheters to reduce bacterial colonization and infection. Ther Apher Dial 2003; 7: 504-9.
71. Choi YS, Lee SB, Hong SR, Lee YM, Song KW, Park MH. Studies on gelatin-based sponges. Part III: a comparative study of cross-linked gelatin/alginate, gelatin/hyaluronate and chitosan/hyaluronate sponges and their application as a wound dressing in full-thickness skin defect of rat. J Mater Sci Mater Med 2001; 12: 67-73.
72. Kawai K, Suzuki S, Tabata Y, Taira T, Ikada Y, Nishimura Y. Development of an artificial dermis preparation capable of silver sulfadiazine release. J Biomed Mater Res 2001; 57: 346-56.
73. Shanmugasundaram N, Sundaraseelan J, Uma S, Selvaraj D, Babu M. Design and delivery of silver sulfadiazine from alginate microspheres-impregnated collagen scaffold. J Biomed Mater Res B Appl Biomater 2006; 77: 378-88.
74. Mi FL, Wu YB, Shyu SS, Schoung JY, Huang YB, Tsai YH, Hao JY. Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. J Biomed Mater Res 2002; 59: 438-49.
75. Lee YM, Kim SS, Park MH, Song KW, Sung YK, Kang IK. beta-Chitin-based wound dressing containing silver sulfur-diazine. J Mater Sci Mater Med 2000; 11: 817-23.
76. Yu SH, Mi FL, Wu YB, Peng CK, Shyu SS, Huang RN. Antibacterial activity of chitosan-alginate sponges incorporating silver sulfadiazine: Effect of ladder-loop transition of interpolyelectrolyte complex and ionic crosslinking on the antibiotic release. J Appl Polym Sci 2005; 98: 538-49.
77. Yu HJ, Xu XY, Chen XS, Lu TC, Zhang PB, Jing XB. Preparation and antibacterial effects of PVA-PVP hydrogels containing silver nanoparticles. J Appl Polym Sci 2007; 103: 125-33.
78. Lee JE, Park JC, Lee KH, Oh SH, Suh H. Laminin modified infection-preventing collagen membrane containing silver sulfadiazine-hyaluronan microparticles. Artif Organs 2002; 26: 521-8.
79. Lee JE, Park JC, Lee KH, Oh SH, Kim JG, Suh H. An infection-preventing bilayered collagen membrane containing antibiotic-loaded hyaluronan microparticles: physical and biological properties. Artif Organs 2002; 26: 636-46.
80. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT. Dendrimer-silver complexes and nanocomposites as antimicrobial agents. Nano letters 2001; 1: 18-21.
81. Ramstedt M, Cheng N, Azzaroni O, Mossialos D, Mathieu HJ, Huck WTS. Synthesis and characterization of poly(3-sulfopropylmethacrylate) brushes for potential antibacterial applications. Langmuir 2007; 23: 3314-21.
82. Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev 2003; 27: 341-53.
83. Schierholz JM, Lucas LJ, Rump A, Pulverer G. Efficacy of silver-coated medical devices. J Hosp Infect 1998; 40: 257-62.
84. Gamelli RL, Paxton TP, O'Reiliy M. Bone marrow toxicity by silver sulfadiazine. Surg Gynecol Obstet 1993; 177: 115-20.
85. Lee AR, Moon HK. Effect of topically applied silver sulfadiazine on fibroblast cell proliferation and biomechanical properties of the wound. Arch Pharm Res 2003; 26: 855-60.
86. Borkow G, Gabbay J. Putting copper into action: copper-impregnated products with potent biocidal activities. FASEB J 2004; 18: 1728-30.
87. Borkow G, Gabbay J. Copper as a biocidal tool. Curr Med Chem 2005; 12: 2163-75.
88. Spinnato JA, 2nd. Mechanism of action of intrauterine contraceptive devices and its relation to informed consent. Am J Obstet Gynecol 1997; 176: 503-6.
89. Haugan T, Skjeldestad FE, Halvorsen LE, Kahn H. A randomized trial on the clinical performance of Nova T380 and Gyne T380 Slimline copper IUDs. Contraception 2007; 75: 171-6.
90. Zhang W, Zhang YH, Ji JH, Zhao J, Yan Q, Chu PK. Antimicrobial properties of copper plasma-modified polyethylene. Polymer 2006; 47: 7441-5.
91. Walker CB, Karpinia K, Baehni P. Chemotherapeutics: antibiotics and other antimicrobials. Periodontol 2000 2004; 36: 146-65.
92. Wu P, Grainger DW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006; 27: 2450-67.
93. Jagpal R, Greco RS. Studies of a graphite-benzalkonium-oxacillin surface. Am Surg 1979; 45: 774-9.
94. Greco RS, Harvey RA. The role of antibiotic bonding in the prevention of vascular prosthetic infections. Ann Surg 1982; 195: 168-71.
95. Kamal GD, Pfaller MA, Rempe LE, Jebson PJ. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA 1991; 265: 2364-8.
96. Piozzi A, Francolini I, Occhiaperti L, Di Rosa R, Ruggeri V, Donelli G, Polyurethanes loaded with antibiotics: influence of polymer-antibiotic interactions on in vitro activity against Staphylococcus epidermidis. J Chemother 2004; 16: 446-52.
97. Piozzi A, Francolini I, Occhiaperti L, Venditti M; Marconi W. Antimicrobial activity of polyurethanes coated with antibiotics: a new approach to the realization of medical devices exempt from microbial colonization. Int J Pharm 2004; 280: 173-83.
98. Schierholz JM, Steinhauser H, Rump AF, Berkels R, Pulverer G. Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features. Biomaterials 1997; 18: 839-44.
99. Kwok CS, Wan C, Hendricks S, Bryers JD, Horbett TA, Ratner BD. Design of infection-resistant antibiotic-releasing polymers: I. Fabrication and formulation. J Control Release 1999; 62: 289-99.
100. Kwok CS, Horbett TA, Ratner BD. Design of infection-resistant antibiotic-releasing polymers. II. Controlled release of antibiotics through a plasma-deposited thin film barrier. J Control Release 1999; 62: 301-11.
101. Liu SJ, Chi PS, Lin SS, Ueng SW, Chan EC, Chen JK. Novel solvent-free fabrication of biodegradable poly-lactic-glycolic acid (PLGA) capsules for antibiotics and rhBMP-2 delivery. Int J Pharm 2007; 330: 45-53.
102. Suzuki A, Terai H, Toyoda H, Namikawa T, Yokota Y, Tsunoda T, Takaoka K. A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: A potential treatment for infected bone defects. J Orthop Res 2006; 24: 327-32.
103. Ueng SW, Lee MS, Lin SS, Chan EC, Liu SJ. Development of a biodegradable alginate carrier system for antibiotics and bone cells. J Orthop Res 2007; 25: 62-72.
104. Price JS, Tencer AF, Arm DM, Bohach GA. Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res 1996; 30: 281-6.
105. Cho SH, Song HR, Koo KH, Jeong ST, Park YJ. Antibiotic-impregnated cement beads in the treatment of chronic osteomyelitis. Bull Hosp Jt Dis 1997; 56: 140-4.
106. Wininger DA, Fass RJ. Antibiotic-impregnated cement and beads for orthopedic infections. Antimicrob Agents Chemother 1996; 40: 2675-9.
107. Wahlig H, Dingeldein E, Bergmann R, Reuss K. The release of gentamicin from polymethylmethacrylate beads. An experimental and pharmacokinetic study. J Bone Joint Surg (Br) 1978; 60: 270-5.
108. van de Belt H, Neut D, Schenk W, van Horn JR, van der Mei HC, Busscher HJ. Gentamicin release from polymethyl-methacrylate bone cements and Staphylococcus aureus biofilm formation. Acta Orthop Scand 2000; 71: 625-9.
109. Neut D, van de Belt H, van Horn JR, van der Mei HC, Busscher HJ. Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. Biomaterials 2003; 24: 1829-31.
110. Neut D, van de Belt H, van Horn JR, van der Mei HC, Busscher HJ. The effect of mixing on gentamicin release from polymethylmethacrylate bone cements. Acta Orthop Scand 2003; 74: 670-6.
111. Garvin K, Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Orthop Relat Res 2005; 437: 105-10.
112. Gerhart TN, Roux RD, Hanff PA, Horowitz GL, Renshaw AA, Hayes WC. Antibiotic-loaded biodegradable bone cement for prophylaxis and treatment of experimental osteomyelitis in rats. J Orthop Res 1993; 11: 250-5.
113. McLaren AC. Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res 2004; 427: 101-6.
114. Schnieders J, Gbureck U, Thull R, Kissel T. Controlled release of gentamicin from calcium phosphate-poly(lactic acid-co-glycolic acid) composite bone cement. Biomaterials 2006; 27: 4239-49.
115. Stigter M, Bezemer J, de Groot K, Layrolle P. Incorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy. J Control Release 2004; 99: 127-37.
116. Tashiro T. Antibacterial and bacterium adsorbing macromolecules. Macromol Mater Eng 2001; 286: 63-87.
117. Sawada H, Tanba K, Tomita T, Kawase T, Baba M, Ide T. Antibacterial activity of fluoroalkylated allyl- and diallyl-ammonium chloride oligomers. Journal of Fluorine Chemistry 1997; 84: 141-4.
118. Tiller JC, Liao CJ, Lewis K, Klibanov AM. Designing surfaces that kill bacteria on contact. Proc Natl Acad Sci U S A 2001; 98: 5981-5.
119. Lin J, Qiu S, Lewis K, Klibanov AM. Mechanism of bactericidal and fungicidal activities of textiles covalently modified with alkylated polyethylenimine. Biotechnol Bioeng 2003; 83: 168-72.
120. Milovic NM, Wang J, Lewis K, Klibanov AM. Immobilized N-alkylated polyethylenimine avidly kills bacteria by rupturing cell membranes with no resistance developed. Biotechnol Bioeng 2005; 90: 715-22.
121. Park D, Wang J, Klibanov AM. One-step, painting-like coating procedures to make surfaces highly and permanently bactericidal. Biotechnol Prog 2006; 22: 584-9.
122. Tiller JC, Lee SB, Lewis K, Klibanov AM. Polymer surfaces derivatized with poly(vinyl-N-hexylpyridinium) kill airborne and waterborne bacteria. Biotechnol Bioeng 2002; 79: 465-71.
123. Haldar J, An D, Alvarez de Cienfuegos L, Chen J, Klibanov AM. Polymeric coatings that inactivate both influenza virus and pathogenic bacteria. Proc Natl Acad Sci U S A 2006; 103: 17667-71.
124. Lin J, Qiu S, Lewis K, Klibanov AM. Bactericidal properties of flat surfaces and nanoparticles derivatized with alkylated polyethylenimines. Biotechnol Prog 2002; 18: 1082-6.
125. Di Martino A, Sittinger M, Risbud MV. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. Biomaterials 2005; 26: 5983-90.
126. Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Mar Biotechnol (NY) 2006; 8: 203-26.
127. Rabea El, Badawy ME, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 2003; 4: 1457-65.
128. Tokura S, Miura Y, Johmen M, Nishi N, Nishimura SI. Induction of drug-specific antibody and the controlled release of drug by 6-O-carboxylmethyl-chitin. J Control Release 1994; 28: 235-41.
129. Liu XF, Guan YL, Yang DZ, Li Z, De Yao K. Antibacterial action of chitosan and carboxymethylated chitosan. J Appl Polym Sci 2001; 79: 1324-35.
130. Jou CH, Lin SM, Yun L, Hwang MC, Yu DG, Chou WL, Lee JS, Yang MC. Biofunctional properties of polyester fibers grafted with chitosan and collagen Polymers for Advanced Technologies 2007; 18: 235-39.
131. Fu J, Ji J, Yuan W, Shen J. Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials 2005; 26: 6684-92.
132. Shi Z, Neoh KG, Kang ET, Wang W. Antibacterial and mechanical properties of bone cement impregnated with chitosan nanoparticles. Biomaterials 2006; 27: 2440-9.
133. Del Curto B, Brunella MF, Giordano C, Pedeferri MP, Valtulina V, Visai L, Cigada A. Decreased bacterial adhesion to surface-treated titanium. Int J Artif Organs 2005; 28: 718-30.
134. Ohko Y, Utsumi Y, Niwa C, Tatsuma T, Kobayakawa K, Satoh Y, Kubota Y, Fujishima A. Self-sterilizing and self-cleaning of silicone catheters coated with TiO(2) photocatalyst thin films: a preclinical work. J Biomed Mater Res 2001; 58: 97-101.
135. Grainger DW. Controlled-release and local delivery of therapeutic antibodies. Expert Opin Biol Ther 2004; 4: 1029-44.
136. Rojas IA, Slunt JB, Grainger DW. Polyurethane coatings release bioactive antibodies to reduce bacterial adhesion. J Control Release 2000; 63: 175-89.
137. Yu H, Grainger DW. Modified release of hydrophilic, hydrophobic and peptide agents from ionized amphiphilic gel networks. J Control Release 1995; 34: 117-27.
138. Gov Y, Bitler A, Dell'Acqua G, Torres JV, Balaban N. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides 2001; 22: 1609-20.
139. Dell'Acqua G, Giacometti A, Cirioni O, Ghiselli R, Saba V, Scalise G, Gov Y, Balaban N. Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J Infect Dis 2004; 190: 318-20.
140. Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, Viticchi C, Del Prete MS, Saba V, Scalise G and others. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis 2003; 187: 625-30.
141. Balaban N, Gov Y, Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, Orlando F, D'Amato G, Saba V, Scalise G and others. A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob Agents Chemother 2004; 48: 2544-50.
142. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Moccheglani F, Silvestri C, Licci A, Skerlavaj B, Zanetti M and others. Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 2006; 27: 2104-10.
143. Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Orlando F, Mocchegiani F, Silvestri C, Licci A, Chiodi L, Lukasiak J and others. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 2006; 27: 1210-6.
144. Ghiselli R, Giacometti A, Cirioni O, Dell'Acqua G, Bergnach C, Orlando F, Mocchegiani F, Silvestri C, Skerlavaj B, Licci A and others. RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Shock 2006; 26: 296-301.
145. Turner MS, Waldherr F, Loessner MJ, Giffard PM. Antimicrobial activity of lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by lactic acid bacteria. Syst Appl Microbiol 2007; 30: 58-67.
146. Shah A, Mend J, Walsh S. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization. Antimicrob Agents Chemother 2004; 48: 2704-7.